Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics reported 11 months of progression-free survival for zovegalisib at its pivotal 400mg twice-daily dose in second-line hormone receptor-positive, HER2-negative breast cancer. Management said the result compares favorably with current standard-of-care capivasertib and that its global pivotal trial is progressing well. The company plans to provide a later-2026 update on expected last-patient-in timing for the study.

Analysis

The investable issue is not the reported efficacy signal but whether zovegalisib can establish a clinically credible therapeutic index at the pivotal dose versus AZN's Truqap. Cross-trial PFS comparisons are not decision-grade: differences in prior CDK4/6 exposure, PIK3CA-mutant enrichment, endocrine backbone, and censoring can materially distort apparent advantage. Until discontinuation rates, hyperglycemia/rash management, and independent-review durability are disclosed, the presentation is more likely to support sentiment than a sustainable valuation reset.

Near-term, RLAY's key catalyst is a concrete enrollment-completion timeline, which de-risks execution but does not shorten the period to registrational data enough to justify paying materially for commercial revenue today. Over 6-18 months, a cleaner safety profile could make zovegalisib strategically valuable to larger oncology franchises, particularly because PI3K-alpha remains a large but poorly tolerated category; conversely, a merely comparable profile leaves RLAY competing against an established AZN commercial platform and potential next-generation PI3K entrants. The principal downside is that pivotal efficacy converges toward standard of care or toxicity forces dose interruptions, compressing both probability of approval and any takeout premium.

Consensus may overvalue the headline efficacy comparison while underweighting trial-design and tolerability risk. For a pre-commercial biotech, the more relevant inflection is whether pivotal enrollment remains on schedule without protocol amendments or evidence of dose-management burden; absent those data, conference optimism is not itself a catalyst.

Key Decisions for Investors

• Maintain RLAY as a watch-list long rather than initiate on conference commentary; reassess after the next enrollment update if management provides a specific last-patient-in date and confirms no material dose-modification or discontinuation signal.
• For event-driven exposure, use a small defined-risk structure only after confirming cash runway through the expected registrational readout: buy RLAY 6-12 month calls or call spreads rather than common equity, with premium at risk capped to 25-50 bps of NAV.
• Avoid a directional short in AZN on this development; Truqap's contribution is too small relative to AZN's diversified earnings base. A more relevant relative-value monitor is RLAY's enterprise value versus oncology peers with late-stage, biomarker-selected assets after pivotal-timing clarity.
• Falsify a constructive RLAY thesis if the enrollment update slips materially, management changes the pivotal dose or eligibility criteria, or future disclosures show toxicity-driven discontinuations that erase any apparent efficacy advantage; these would warrant reducing exposure before registrational data.